title: Topical nepafenac in treatment of acute central serous chorioretinopathy.
abstract: This study had been performed to investigate the anatomic and functional outcomes of nepafenac 0.1% therapy in acute central serous chorioretinopathy (CSC). The medical records of 30 patients with acute CSC were reviewed for a total of 31 eye charts. Seventeen eye records of 16 patients who were treated with topical nepafenac 0.1% three times daily for four weeks and continued until complete resolution of subretinal fluid were appraised. Fourteen patients with acute CSC (a total of 14 eye records) who did not receive treatment served as the control group also had been recorded. The proportion of eyes with complete resolution of subretinal fluid, serial changes in the mean best corrected visual acuity (BCVA), and the mean central foveal thickness (CFT) at 6 months of therapy were the outcomes measured. Mean age was 42.6±8.2 years in the treatment group and 41.1±7.1 years in the control group (p=0.85). At 6 months, 14 eyes (82.3%) in the treatment group and 6 eyes (42.8%) in the control group revealed a complete resolution in the subretinal fluid (p=0.02). In the treatment group, mean BCVA (LogMAR) significantly improved from 0.19±0.17 at baseline to 0.09±0.12 at 6 months (p=0.01). In the control group, mean BCVA (LogMAR) was 0.13±0.14 at baseline and decreased to 0.1±0.11 at 6 months (p=0.28). In the treatment group, mean CFT was 349±115 µm at baseline and significantly improved to 221±95 µm at 6 months (p<0.01). In the control group, mean CFT declined from 391±138 µm at baseline to 301±125 µm at 6 months (p=0.06). No treatment-related ocular or systemic side effects were observed. In conclusion, nepafenac 0.1% has the potential to treatment acute CSC. Further trials are warranted to study its safety and efficacy for this disease.
authors.affiliation: Beyoglu Eye Training and Research Hospital, Bereketzade Cami Sok, Istanbul, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Alkin
authors.affiliation: Beyoglu Eye Training and Research Hospital, Bereketzade Cami Sok, Istanbul, Turkey.
authors.forename: Ozen Ayranci
authors.initials: OA
authors.lastname: Osmanbasoglu
authors.affiliation: Beyoglu Eye Training and Research Hospital, Bereketzade Cami Sok, Istanbul, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Ozkaya
authors.affiliation: Beyoglu Eye Training and Research Hospital, Bereketzade Cami Sok, Istanbul, Turkey.
authors.forename: Gonul
authors.initials: G
authors.lastname: Karatas
authors.affiliation: Beyoglu Eye Training and Research Hospital, Bereketzade Cami Sok, Istanbul, Turkey.
authors.forename: Ahmet Taylan
authors.initials: AT
authors.lastname: Yazici
keywords: Acute Central Serous Chorioretinopathy; Central Foveal Thickness; LogMAR; Subretinal Fluid; Topical Nepafenac; Visual Acuity